Compare Bristol-Myers Squibb Co (BMY) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs KB Financial Group, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.93 (market cap $129.94B), while KB Financial Group, Inc. trades at $117.57 (market cap $41.21B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.2× KB Financial Group, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | KB | |
|---|---|---|
Market Cap | $129.94B | $41.21B |
Sector | Health | Financials |
52-Week High | $65.89 | $124.01 |
52-Week Low | $42.60 | $77.50 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
KB Financial Group (KB) trades at $118.00, down 2.26% today, with a bullish technical signal from moving averages. The stock shows strong fundamental performance with consistent earnings beats, 27.82% net income margin, and attractive valuation at P/E of 10.36 and P/B of 0.98. Recent news highlights momentum potential and diversification into non-banking segments, which now contribute 43% of earnings.
Outlook remains positive with earnings growth and shareholder returns as key catalysts, though risks include volatile operating environment and heavy investing cash outflows. Analyst consensus leans cautious with 67% hold ratings, suggesting potential upside requires continued execution on diversification and fee income growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
